Precision Prevention of Early-Onset Cardiovascular-Kidney-Metabolic Disease in Children

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Nature Metabolism  https://doi.org/10.1038/s42255-026-01589-7
Dr. Joshua M. Landman et al.

Points

Multi institutional researchers identified circulating protein signatures of cardiovascular kidney metabolic disease in children as young as eight years old that mirror adult disease biomarkers.
Investigators analyzed twenty five physical phenotypes across two hundred seventy three Hispanic children to map proteomic signatures that were validated against over twenty eight thousand adult records.
Proteomic patterns strongly correlated with beta cell function, insulin sensitivity, hepatic homeostasis, inflammation, and cholesterol metabolism across both pediatric and adult cohorts.
Identified disease proteins overlapped with pathways modified by semaglutide, coinciding with a nearly six hundred percent surge in pediatric GLP-1 receptor agonist prescriptions from 2020 to 2023.
Study authors concluded that pediatric proteomic profiling provides an early window for precision medicine interventions to prevent irreversible cardiovascular damage decades before clinical symptom onset.

Summary

This study evaluated circulating proteomic signatures in pediatric populations to establish early risk profiles for cardiovascular-kidney-metabolic disease (CKMD) and predict long-term adult clinical outcomes. Given that pathological roots of CKMD emerge before 20 years of age and standard adult risk thresholds fail to detect high-risk pediatric patients, early biomarker identification is critical. The research sought to determine whether pediatric proteomic signatures map directly to adult cardiometabolic disease mechanisms and evaluate their potential responsiveness to targeted therapeutic interventions.

Using machine-learning approaches, the investigators linked 25 distinct CKMD phenotypes—spanning liver, adipose, vascular, and dysglycemia traits—to the circulating proteome in 273 Hispanic or Latino children and adolescents (mean age 13.1 ± 2.7 years; 53% female) from the Border Health Research Cohort in Cameron County, Texas, where over one-third displayed clinical CKMD traits. These pediatric phenotype-proteome relationships were then validated against 685 community-matched adults and 28,256 adult profiles from the UK Biobank repository. The analysis demonstrated high cross-generational concordance, linking pediatric protein patterns directly to adult pancreatic beta-cell health, insulin sensitivity, hepatic homeostasis, systemic inflammation, and cholesterol metabolism.

Notably, pediatric protein signatures associated with CKMD overlapped with molecular targets modifiable by glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, which saw pediatric prescriptions surge by nearly 600% between 2020 and 2023. These findings confirm that adult CKMD risk is biologically embedded within the pediatric proteome starting as early as age 8. The authors conclude that proteomic profiling enables precision prevention decades before clinical manifestation, offering a critical therapeutic window to interrupt disease progression using targeted pharmacological and lifestyle interventions.

Link to the article: https://www.nature.com/articles/s42255-026-01589-7

References

Landman, J. M., Highland, H. M., Perry, A. S., Howard, A. G., Sheng, Q., Lorenz, A., Palmer, A. B., Zhao, S., Zhu, W., Zhang, X., Buchanan, V. L., Frankel, E. G., Roshani, R., Scartozzi, A., Farber-Eger, E. H., Anwar, M. Y., Sprinkles, J. K., Breidenbach, A., Wang, T.-C., … Shah, R. V. (2026). Paediatric proteomic signatures of cardiometabolic disease-associated traits predict adult disease outcomes. Nature Metabolism, 1–16. https://doi.org/10.1038/s42255-026-01589-7